← Back to all trials
Not Yet Recruiting
NCT07729852
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
Conditions: Multiple System Atrophy
Sex: All
Healthy volunteers: No
Phase: PHASE2
Enrollment: 5
Sponsor: Alterity Therapeutics
Location: Hôpital Pierre-Paul Riquet Toulouse Midi-Pyrenees
Summary
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
Eligibility Criteria
Inclusion Criteria:
* Completed Alterity protocol ATH434-201.
* Expected to benefit from treatment from treatment with ATH434, in the opinion of the Investigator.
Exclusion Criteria:
* Discontinued prior ATH434 treatment (ATH434-201) for any reason.
* Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the Investigator's opinion.
Source: ClinicalTrials.gov (NCT07729852). StuddyBuddy aggregates publicly available trial information.
